Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Topoisomerase IIa amplifications may be predictive marker for effect of epirubicin therapy
December 29th, 2005
Topoisomerase IIa amplifications may be a predictive marker for the effect of adjuvant epirubicin therapy for primary breast cancer. According to scientists in Denmark, "The aim of this study was to evaluate the predictive value of HER2 and topoisomerase II alpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients." "In the Danish Breast Cancer Cooperative Group trial 89D, 980 pre- and postmenopausal primary patients were randomly allocated to either CMF (cyclophosphamide, methotrexate, and fluorouracil; n=500) or CEF (cyclophosphamide, epirubicin, and fluorouracil; n=480) times 9, between January 1990 and...
Source: Women's Health Weekly (2005-12-29)
|
